Theophylline for chronic obstructive pulmonary disease? .... Time to move on

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 7, 2010, Pages 868-869

  Rabe, Klaus F ^a   Hiemstra, P S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; HISTONE DEACETYLASE 2; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STEROID; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; COUNSELING; CYTOKINE RELEASE; DISEASE EXACERBATION; DOSE RESPONSE; EDITORIAL; ENZYME ACTIVITY; EXERCISE; HEALTH PROGRAM; HEALTH STATUS; HUMAN; LUNG FUNCTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; NOTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTI-INFLAMMATORY AGENTS; DRUG RESISTANCE; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE;

EID: 77958158463     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201008-1271ED     Document Type: Editorial

References (12)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel WC, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
3. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-338.
4. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, ten Hacken NH, Sont JK, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151:517-527.
5. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694.
6. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, MacNee W, et al. COPD phenotypes: the future of COPD. Am J Respir.Crit Care Med 2010;182:598-604.
7. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-733.
8. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451-464.
9. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-695.
10. Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009;64:424-429.
11. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009;179:542-548.
12. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliott WM, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide-3-kinase-{delta} with theophylline reverses corticosteroid insensitivity COPD. Am J Respir Crit Care Med 2010;897-904.